For media inquiries, please contact Erich Horsley at: media@biosplice.com

2026

Date	Title
Jan 06	Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis

2024

Date	Title
Apr 18	Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results

2023

Date	Title
Nov 13	Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis

2022

Date	Title
Nov 11	Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial

2021

Date	Title
Sep 15	Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
Sep 15	FierceBiotech: Haisco to Pay $140M to Get the Ball rolling on Biosplice's Phase 3 Osteoarthritis Drug in China
Jul 22	Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
Apr 26	Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
Apr 22	Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea
Apr 15	Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance its Alternative Splicing Platform

2020

Date	Title
Nov 17	Biosplice Chief Medical Officer, Dr. Yusuf Yazici, Discusses Lorecivivint on the Podcast “ACR on Air”
May 22	Biosplice Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

Web Analytics